VolitonRx's research-use-only kits can be used to examine patterns in circulating nucleosomes in disease models, preclinical testing, and clinical trials.
The company is working with DKFZ to evaluate its NuQ test, which can identify chromosome fragments circulating in blood and analyze them for epigenetic modifications.
The blood-based assay, which uses the company's nucleosome detection technology, is the first of several that will be bundled together as a test for cancer diagnosis.
The study will evaluate the ability of VolitionRx's technology to detect prostate cancer and to distinguish different prostate conditions and healthy samples.
The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells.
The firm, which was previously listed on the over-the-counter market, anticipates $8.5 million in net proceeds from the offering.
SingaporeGeneralHospitalwill provide blood and tissue samples for the pilot study, which is meant to establish the feasibility of VolitionRx's technology.
The study will evaluate VolitionRx's Nucleosomics platform in blood tests, adding to existing studies assessing the firm's technology at the university.
NEW YORK (GenomeWeb) – VolitionRx today announced a collaboration with the University of Oxford on a clinical study to develop biomarkers for the diagnosis of endometriosis using the firm's Nucleosomics platform.
NEW YORK (GenomeWeb News) – VolitionRx said today it has reached a deal with Active Motif to co-exclusively distribute VolitionRx's NuQ product line in Europe, the US, and Japan.
Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.
US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.
In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.